Gain Therapeutics, Inc.
GANX
$1.80
$0.063.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.77M | -4.49M | -8.14M | -4.01M | -4.72M |
| Total Depreciation and Amortization | 9.30K | 9.60K | 9.60K | 8.50K | 11.60K |
| Total Amortization of Deferred Charges | 12.00K | 12.00K | 11.00K | 12.00K | 12.00K |
| Total Other Non-Cash Items | 913.30K | 313.30K | 1.32M | -9.70K | 419.40K |
| Change in Net Operating Assets | -621.00K | -1.93M | 1.05M | 416.80K | -1.38M |
| Cash from Operations | -3.45M | -6.08M | -5.76M | -3.59M | -5.66M |
| Capital Expenditure | -900.00 | 0.00 | -21.50K | -- | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.50K | 0.00 | 2.02M | 3.02M | 3.14M |
| Cash from Investing | -43.40K | 0.00 | 2.00M | 3.02M | 3.14M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -22.80K | -23.10K | -22.10K | -22.90K | -22.60K |
| Issuance of Common Stock | 2.34M | 831.80K | 10.06M | 157.90K | 9.58M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | -280.90K | -- |
| Cash from Financing | 2.31M | 808.70K | 10.04M | -145.80K | 9.56M |
| Foreign Exchange rate Adjustments | -480.60K | 382.80K | 13.10K | -442.50K | 483.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.67M | -4.88M | 6.30M | -1.16M | 7.53M |